Therapeutic solutions company Sanofi has appointed Bill Sibold as Executive Vice President of Sanofi Genzyme.
In this role, Sibold will be a member of the Executive Committee. He succeeds David Meeker, who will leave the company at the end of June after a 23-year career with Genzyme and Sanofi.
Sibold currently serves as head of Sanofi Genzyme's Global Multiple Sclerosis, Oncology and Immunology organisation, where he has led preparation for the global launches of Dupilumab and Sarilumab.
He joined Sanofi in 2011 as head of the MS franchise where he oversaw the successful launches of Aubagio and Lemtrada.
As head of Sanofi Genzyme, Sibold will now lead the company's efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology.
Sibold is from Canada and has more than 25 years of experience in the biopharmaceutical industry since starting his career with Eli Lilly.
He held a number of leadership positions within Biogen, including driving their US commercial operations in neurology, oncology and rheumatology and general management of Biogen's Australian and Asia-Pacific business.
In addition to his time with Biogen, Sibold also served as the Chief Commercial Officer of Avanir Pharmaceuticals.
He holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.
